Results 161 to 170 of about 163,856 (309)

Clinical Images: Methotrexate‐induced melanonychia

Arthritis &Rheumatology, EarlyView.
Yoshinori Taniguchi, Hirotaka Yamamoto
wiley   +1 more source

Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab

British Journal of Clinical Pharmacology, EarlyView.
Aims Early clinical development of novel psoriasis therapies is hampered by a decreasing number of moderate‐to‐severe psoriasis patients eligible for participation in trials since efficacious treatments, such as biologics, have become widely available.
Jannik Rousel, Menthe E. Bergmans, Lisa J. Bruijnincx, Sissi Lin, Tessa Niemeyer‐van der Kolk, Roman Bohoslavsky, Yalçin Yavuz, Naomi B. Klarenbeek, Joke A. Bouwstra, Robert Rissmann, Martijn B. A. van Doorn, the Next‐Generation ImmunoDermatology Consortium (NGID)   +11 more
wiley   +1 more source

Treating rheumatoid arthritis in Zanzibar: a cost effectiveness study comparing conventional, biologic, and targeted-synthetic disease modifying anti-rheumatic drugs. [PDF]

Front Med (Lausanne)
Said SS, Kühl MJ, Fevang BS, Nystad TW, Johansson KA.   +4 more
europepmc   +1 more source

The Effect of Methotrexate on Transformation and Mitosis of Normal Human Blood Lymphocytes In Vitro [PDF]

, 1974
L. A. Rozenszajn, Judith Radnay
openalex   +1 more source

Sarcoidosis revealed by recurrent dactylitis.

Arthritis &Rheumatology, Accepted Article.
Thomas Subervie, Thibault Willaume, Amin Maazouzi, Jacques‐Eric Gottenberg, Jean Sibilia, Noëlle Weingertner, Eden Sebbag, Marc Scherlinger   +7 more
wiley   +1 more source

Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate).
Derek Z. Yang, Li Zhou, Jennifer A. Winton, Kyle T. Matschke, Constantino Kantaridis, Kristine Doyle, Kimberly C. Lee, Naihan Chen, Yuanyuan Zhang, Weiwei Tan   +9 more
wiley   +1 more source

Prevalence and Clinical Significance of Potential Drug-Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study. [PDF]

Cancers (Basel)
Zekavat OR, Zarsanj N, Sadeghdoust A, Lavu A, Bordbar M, Eltonsy S, Peymani P.   +6 more
europepmc   +1 more source

Methotrexate Pharmacokinetics

, 1971
Kenneth B. Bischoff, Robert L. Dedrick, Daniel S. Zaharko, James Longstreth   +3 more
openalex   +1 more source

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice

British Journal of Clinical Pharmacology, EarlyView.
Aims Adherence to disease‐modifying antirheumatic drugs (DMARDs) has been associated with improved treatment outcomes, but how adherence is reported ranges between studies. We therefore aimed to determine how nonadherence to DMARDs used to treat rheumatoid arthritis (RA) has been measured and to report the nonadherence rate with each measure identified.
Lauren Fraser, Nagham Ailabouni, Lisa Kalisch Ellett, Jiun Ming Tan, Anthea Freeman, Susanna M. Proudman, Emily Reeve, Michael D. Wiese   +7 more
wiley   +1 more source

Methotrexate Scarcity Among Children's Oncology Group Institutions: Results of a Multinational Survey. [PDF]

Oncologist
Menig S, Militano O, Ostrenga A, Bernhardt MB, Lee B, Unguru Y.   +5 more
europepmc   +1 more source